Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California

Background: Bedaquiline (BDQ) is recommended for the treatment of multidrug-resistant tuberculosis (MDR TB), however, it has the potential to prolong QTc interval. We assessed the frequency and severity of QTc prolongation in patients receiving BDQ in California. Methods: Based on chart review for p...

Full description

Bibliographic Details
Main Authors:	Shereen Katrak, Phil Lowenthal, Richard Shen, Lisa True, Leslie Henry, Pennan Barry
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:	Tuberculosis Multidrug-resistant Treatment Safety Adverse event Bedaquiline
Online Access:	http://www.sciencedirect.com/science/article/pii/S240557942100005X

Similar Items

Identification of urine biomarkers predictive of prolonged QTc interval in multidrug-resistant tuberculosis patients treated with bedaquiline
by: Jiajia Yu, et al.
Published: (2024-05-01)

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
by: Alena Skrahina, et al.
Published: (2016-01-01)

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis
by: Yuhong Liu, et al.
Published: (2021-01-01)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
by: Jian Du, et al.
Published: (2021-05-01)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
by: Citra Cesilia, et al.
Published: (2023-01-01)

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea
by: Tae Sun Shim, et al.
Published: (2023-01-01)

Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients
by: Jingtao Gao, et al.
Published: (2020-11-01)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021-03-01)

Bedaquiline: Current status and future perspectives
by: Saeed Khoshnood, et al.
Published: (2021-06-01)

Clinical course of pregnancy and postpartum in a multidrug-resistant tuberculosis/HIV co-infected patient receiving bedaquiline-containing regimen as antimycobacterial therapy
by: О.М. Raznatovska, et al.
Published: (2019-12-01)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
by: Lawrence Mbuagbaw, et al.
Published: (2019-05-01)

Bedaquiline in the treatment regimen of multidrugresistant tuberculosis (clinical observation)
by: V. A. Aksenova, et al.
Published: (2020-11-01)

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
by: Jinmeng Li, et al.
Published: (2021-09-01)

The use of bedaquiline in children in the treatment of multidrug-resistant tuberculosis
by: Valentina Romanenko, et al.
Published: (2024-12-01)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
by: Rong Li, et al.
Published: (2023-08-01)

Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients
by: Oki Nugraha Putra, et al.
Published: (2024-12-01)

Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis
by: V. A. Aksenova, et al.
Published: (2021-10-01)

Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
by: Ming-Gui Wang, et al.
Published: (2021-09-01)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
by: Ge Shao, et al.
Published: (2023-03-01)

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis
by: AmirHossein Akbari Aghababa, et al.
Published: (2024-08-01)

New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline
by: Ekaterina Sokolskaya, et al.
Published: (2024-12-01)

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
by: Anna Starshinova, et al.
Published: (2022-11-01)

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia
by: Gunar Günther, et al.
Published: (2024-03-01)

Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01)

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid
by: Qing Chen, et al.
Published: (2024-07-01)

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
by: Catherine Berry, et al.
Published: (2022-06-01)

Acquired bedaquiline and fluoroquinolones resistance during treatment follow-up in Oromia Region, North Shewa, Ethiopia
by: Getu Diriba, et al.
Published: (2024-01-01)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
by: Jay Achar, et al.
Published: (2017-10-01)

Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study
by: Ju Hwan Kim, et al.
Published: (2023-08-01)

Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil – a real-world evidence study using a retrospective design
by: Ana Paula Santos, et al.
Published: (2024-10-01)

Bedaquiline in the treatment of extensively drugresistant tuberculosis
by: T. I. Morozova, et al.
Published: (2022-04-01)

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis
by: Obaid Ur Rehman, et al.
Published: (2024-02-01)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
by: Yangming Ding, et al.
Published: (2023-10-01)

Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA Adverse Event Reporting System database from 2013 to 2024
by: Sheng Wei, et al.
Published: (2024-12-01)

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01)

Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt
by: Magda Afifi, et al.
Published: (2024-07-01)

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia
by: Soedarsono Soedarsono, et al.
Published: (2024-06-01)